Cancer Science最新文献

筛选
英文 中文
Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance. 奥西替尼治疗第一代EGFR- tki耐药后获得性T790M和EGFR扩增的EGFR突变NSCLC患者
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-31 DOI: 10.1111/cas.16437
Yidan Zhang, Yingqi Xu, Jianlin Xu, Hua Zhong, Jinjing Xia, Runbo Zhong
{"title":"Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.","authors":"Yidan Zhang, Yingqi Xu, Jianlin Xu, Hua Zhong, Jinjing Xia, Runbo Zhong","doi":"10.1111/cas.16437","DOIUrl":"https://doi.org/10.1111/cas.16437","url":null,"abstract":"<p><p>Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the standard therapy for patients harboring T790M after first-generation EGFR-TKI resistance. However, the impact of acquired EGFR amplification on the efficacy of third-generation EGFR-TKI against T790M remains uncertain. We aimed to investigate whether the presence of acquired EGFR amplification after first-generation EGFR-TKI resistance influences the efficacy of third-generation EGFR-TKI in patients with advanced non-small-cell lung cancer (NSCLC). We reviewed data from 275 advanced NSCLC patients harboring T790M after first-generation EGFR-TKI resistance. Patients were categorized into two groups based on the presence or absence of acquired EGFR amplification identified through next-generation sequencing (NGS) after first-line EGFR-TKI treatment. We evaluated the efficacy of osimertinib used as a second-line treatment. Among these patients, 59 exhibited acquired EGFR amplification, while 216 did not. The median progression-free survival (PFS) was 12.20 months in the EGFR amplification group and 12.03 months in the non-amplification group (p = 0.011), with median overall survival (OS) of 33.90 months and 23.30 months, respectively (p = 0.164). Multivariate analysis of PFS revealed that acquired EGFR amplification and EGFR 19del were independent prognostic factors for patients with T790M undergoing osimertinib. Additionally, subgroup analysis indicated a prolonged PFS in patients with EGFR 19del compared to those with EGFR 21L858R (p = 0.034) in the EGFR amplification group. Following first-generation EGFR-TKI resistance, advanced EGFR-mutant NSCLC patients harboring both acquired T790M and EGFR amplification are likely to experience enhanced PFS with osimertinib. This phenomenon is particularly noteworthy among individuals with EGFR 19del.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt. 对KRAS抑制剂的耐药机制:癌细胞利用正常细胞机制进行适应。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-27 DOI: 10.1111/cas.16441
Noritaka Tanaka, Hiromichi Ebi
{"title":"Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt.","authors":"Noritaka Tanaka, Hiromichi Ebi","doi":"10.1111/cas.16441","DOIUrl":"https://doi.org/10.1111/cas.16441","url":null,"abstract":"<p><p>KRAS was long deemed undruggable until the discovery of the switch-II pocket facilitated the development of specific KRAS inhibitors. Despite their introduction into clinical practice, resistance mechanisms can limit their effectiveness. Initially, tumors rely on mutant KRAS, but as they progress, they may shift to alternative pathways, resulting in intrinsic resistance. This resistance can stem from mechanisms like epithelial-to-mesenchymal transition (EMT), YAP activation, or KEAP1 mutations. KRAS inhibition often triggers cellular rewiring to counteract therapeutic pressure. For instance, feedback reactivation of signaling pathways such as MAPK, mediated by receptor tyrosine kinases, supports tumor cell survival. Inhibiting KRAS disrupts protein homeostasis, but reactivation of MAPK or AKT can restore it, aiding tumor cell survival. KRAS inhibition also causes metabolic reprogramming and protein re-localization. The re-localization of E-cadherin and Scribble from the membrane to the cytosol causes YAP to translocate to the nucleus, where it drives MRAS transcription, leading to MAPK reactivation. Emerging evidence indicates that changes in cell identity, such as mucinous differentiation, shifts from alveolar type 2 to type 1 cells, or lineage switching from adenocarcinoma to squamous cell carcinoma, also contribute to resistance. In addition to these nongenetic mechanisms, secondary mutations in KRAS or alterations in upstream/downstream signaling proteins can cause acquired resistance. Secondary mutations in the switch-II pocket disrupt drug binding, and known oncogenic mutations affect drug efficacy. Overcoming these resistance mechanisms involves enhancing the efficacy of drugs targeting mutant KRAS, developing broad-spectrum inhibitors, combining therapies targeting multiple pathways, and integrating immune checkpoint inhibitors.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient-Derived Organoids on ERK and AMPK Activity. 定量实时成像显示PDAC患者来源的类器官对ERK和AMPK活性的相位依赖性。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-27 DOI: 10.1111/cas.16439
Shoko Tsukamoto, Ye Huaze, Zhang Weisheng, Akihito Machinaga, Nobuyuki Kakiuchi, Seishi Ogawa, Hiroshi Seno, Shigeki Higashiyama, Michiyuki Matsuda, Toru Hiratsuka
{"title":"Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient-Derived Organoids on ERK and AMPK Activity.","authors":"Shoko Tsukamoto, Ye Huaze, Zhang Weisheng, Akihito Machinaga, Nobuyuki Kakiuchi, Seishi Ogawa, Hiroshi Seno, Shigeki Higashiyama, Michiyuki Matsuda, Toru Hiratsuka","doi":"10.1111/cas.16439","DOIUrl":"https://doi.org/10.1111/cas.16439","url":null,"abstract":"<p><p>Patient-derived organoids represent a novel platform to recapitulate the cancer cells in the patient tissue. While cancer heterogeneity has been extensively studied by a number of omics approaches, little is known about the spatiotemporal kinase activity dynamics. Here we applied a live imaging approach to organoids derived from 10 pancreatic ductal adenocarcinoma (PDAC) patients to comprehensively understand their heterogeneous growth potential and drug responses. By automated wide-area image acquisitions and analyses, the PDAC cells were non-selectively observed to evaluate their heterogeneous growth patterns. We monitored single-cell ERK and AMPK activities to relate cellular dynamics to molecular dynamics. Furthermore, we evaluated two anti-cancer drugs, a MEK inhibitor, PD0325901, and an autophagy inhibitor, hydroxychloroquine (HCQ), by our analysis platform. Our analyses revealed a phase-dependent regulation of PDAC organoid growth, where ERK activity is necessary for the early phase and AMPK activity is necessary for the late stage of organoid growth. Consistently, we found PD0325901 and HCQ target distinct organoid populations, revealing their combination is widely effective to the heterogeneous cancer cell population in a range of PDAC patient-derived organoid lines. Together, our live imaging quantitatively characterized the growth and drug sensitivity of human PDAC organoids at multiple levels: in single cells, single organoids, and individual patients. This study will pave the way for understanding the cancer heterogeneity and promote the development of new drugs that eradicate intractable cancer.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-Cell RNA Sequencing Reveals the Tumor Heterogeneity and Immunosuppressive Microenvironment in Urothelial Carcinoma. 单细胞RNA测序揭示尿路上皮癌的肿瘤异质性和免疫抑制微环境。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-26 DOI: 10.1111/cas.16436
Tianqi Lyu, Kerong Wu, Yincong Zhou, Tong Kong, Lin Li, Kaizhe Wang, Pan Fu, Pengyao Wei, Ming Chen, Jianping Zheng
{"title":"Single-Cell RNA Sequencing Reveals the Tumor Heterogeneity and Immunosuppressive Microenvironment in Urothelial Carcinoma.","authors":"Tianqi Lyu, Kerong Wu, Yincong Zhou, Tong Kong, Lin Li, Kaizhe Wang, Pan Fu, Pengyao Wei, Ming Chen, Jianping Zheng","doi":"10.1111/cas.16436","DOIUrl":"https://doi.org/10.1111/cas.16436","url":null,"abstract":"<p><p>Urothelial carcinoma (UC) can arise from either the lower urinary tract or the upper tract; they represent different disease entities and require different clinical treatment strategies. A full understanding of the cellular characteristics in UC may guide the development of novel therapies. Here, we performed single-cell transcriptome analysis from four patients with UC of the bladder (UCB), five patients with UC of the ureter (UCU), and four patients with UC of the renal pelvis (UCRP) to develop a comprehensive cell atlas of UC. We found the rare epithelial cell subtype EP9 with epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) features, and specifically expressed SOX6, which was associated with poor prognosis. We also found that ACKR1+ endothelial cells and inflammatory cancer-associated fibroblasts (iCAFs) were more enriched in UCU, which may promote pathogenesis. While ESM1+ endothelial cells may more actively participate in UCB and UCRP tumorigenesis by promoting angiogenesis. Additionally, CD8 + effector T cells were more enriched in UCU and UCRP patients, while Tregs were mainly enriched in UCB tumors. C1QC+ macrophages and LAMP3+ dendritic cells were more enriched in UCB, which is closely related to the formation of the heterogeneous immunosuppressive microenvironment. Furthermore, we found strong interactions between iCAFs, EP9, and Endo_ESM1, and different degrees of activation of the FGF-FGFR3 axis and immune checkpoint pathway were observed in different UC subtypes. Our study elucidated the cellular heterogeneity and the components of the microenvironment in UC arising from the upper and lower urinary tracts and provided novel therapeutic targets.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation. TIM-3标志着同种异体干细胞移植后复发的可测量的残留白血病干细胞。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-26 DOI: 10.1111/cas.16431
Teppei Sakoda, Yoshikane Kikushige, Hidetoshi Irifune, Gentaro Kawano, Takuya Harada, Yuichiro Semba, Masayasu Hayashi, Takahiro Shima, Yasuo Mori, Tetsuya Eto, Tomohiko Kamimura, Hiromi Iwasaki, Ryosuke Ogawa, Goichi Yoshimoto, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi
{"title":"TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.","authors":"Teppei Sakoda, Yoshikane Kikushige, Hidetoshi Irifune, Gentaro Kawano, Takuya Harada, Yuichiro Semba, Masayasu Hayashi, Takahiro Shima, Yasuo Mori, Tetsuya Eto, Tomohiko Kamimura, Hiromi Iwasaki, Ryosuke Ogawa, Goichi Yoshimoto, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi","doi":"10.1111/cas.16431","DOIUrl":"https://doi.org/10.1111/cas.16431","url":null,"abstract":"<p><p>In this study, we investigated the measurable residual leukemic stem cell (MR-LSC) population after allogeneic stem cell transplantation (allo-SCT) for high-risk acute myeloid leukemia (AML), utilizing T-cell immunoglobulin mucin-3 (TIM-3) expression as a functional marker of AML leukemic stem cells (LSCs). Analysis of the CD34<sup>+</sup>CD38<sup>-</sup> fraction of bone marrow cells immediately after achievement of engraftment revealed the presence of both TIM-3<sup>+</sup>LSCs and TIM-3<sup>-</sup> donor hematopoietic stem cells (HSCs) at varying ratios. Genetic analysis confirmed that TIM-3<sup>+</sup> cells harbored patient-specific mutations identical to those found in AML clones, whereas TIM-3<sup>-</sup> cells did not, indicating that TIM-3<sup>+</sup>CD34<sup>+</sup>CD38<sup>-</sup> cells represent residual AML LSCs. In 92 allo-SCT occasions involving 83 AML patients, we enumerated the frequencies of TIM-3<sup>+</sup>LSCs immediately after achieving hematologic complete remission with complete donor cell chimerism. Notably, only 22.2% of patients who achieved a TIM-3<sup>+</sup>MR-LSC<sup>low</sup> status (<60%) experienced relapse, with a median event-free survival (EFS) of 1581 days (median follow-up duration was 2177 days among event-free survivors). Conversely, 87.5% of patients with TIM-3<sup>+</sup>MR-LSC<sup>int/high</sup> (≥60%) relapsed, with a median EFS of 140.5 days. Furthermore, MR-LSC status emerged as a significant independent risk factor for relapse (hazard ratio, 8.56; p < 0.0001), surpassing the impact of patient disease status prior to allo-SCT, including failure to achieve complete remission (hazard ratio, 1.98; p = 0.048). These findings suggest that evaluating TIM-3<sup>+</sup> MR-LSCs immediately after engraftment, which reflects the competitive reconstitution of residual TIM-3<sup>+</sup> LSCs and donor HSCs, may be valuable for predicting outcomes in AML patients undergoing allo-SCT.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Long Noncoding RNA OVAAL Enhances Nucleotide Synthesis Through Pyruvate Carboxylase to Promote 5-Fluorouracil Resistance in Gastric Cancer". 更正“长链非编码RNA OVAAL通过丙酮酸羧化酶促进核苷酸合成促进胃癌5-氟尿嘧啶耐药”。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-26 DOI: 10.1111/cas.16444
{"title":"Correction to \"Long Noncoding RNA OVAAL Enhances Nucleotide Synthesis Through Pyruvate Carboxylase to Promote 5-Fluorouracil Resistance in Gastric Cancer\".","authors":"","doi":"10.1111/cas.16444","DOIUrl":"https://doi.org/10.1111/cas.16444","url":null,"abstract":"","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma. 在卵巢癌肉瘤中,SMARCA4的缺失通过上皮-间质转化诱导肉瘤发生。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-23 DOI: 10.1111/cas.16423
Yoshihiro Katayama, Takeshi Iwasaki, Takeo Yamamoto, Naomi Shimada, Miya Nakashima, Masato Toya, Fumiya Narutomi, Takumi Tomonaga, Kiyoko Kato, Yoshinao Oda
{"title":"Loss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma.","authors":"Yoshihiro Katayama, Takeshi Iwasaki, Takeo Yamamoto, Naomi Shimada, Miya Nakashima, Masato Toya, Fumiya Narutomi, Takumi Tomonaga, Kiyoko Kato, Yoshinao Oda","doi":"10.1111/cas.16423","DOIUrl":"https://doi.org/10.1111/cas.16423","url":null,"abstract":"<p><p>Ovarian carcinosarcoma (OCS) is a rare and aggressive tumor, and the development of its sarcomatous component is believed to be due to epithelial-mesenchymal transition (EMT). The SWIch/sucrose nonfermentable chromatin remodeling factor (CRF) is closely related to EMT; however, the relationship between CRF and EMT in OCS remains unclear. In this study, we analyzed the protein expression of CRFs, including ARID1A and SMARCA4, and their downstream mRNA expression in 28 OCS cases, two fallopian tube CS cases, and one peritoneal CS case. ARID1A and SMARCA4 exhibited a histological type-specific loss of protein expression in 5 of 11 (45%) endometrioid cases and all 5 serous/homologous OCS cases, respectively. The mRNA analysis suggested that sarcomatogenesis is induced by the transforming growth factor-β and Hippo signaling pathways, both of which regulate YAP1. Immunostaining for YAP1 suggested YAP1-associated sarcomatogenesis in the CRF-retained group, whereas YAP1-unassociated sarcomatogenesis was suggested in the CRF-reduced group. High-grade serous carcinoma cell line experiments showed that the transcriptome of the SMARCA4-knockdown group showed lower expression of the epithelial gene CDH1 and higher expression of mesenchymal genes such as VIM, ZEB1, and SNAI1 than the control group. Moreover, cell adhesion disappeared and cell morphology changed to a spindle shape, indicating sarcomatogenesis. In conclusion, this study reveals a mechanism for sarcoma development in OCS and provides novel therapeutic possibilities.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142883373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis. 评估乳腺癌中 MAGE-A4 的表达及其对预后的影响。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-20 DOI: 10.1111/cas.16433
Kaho Nakamura, Kanako Saito, Chihiro Higashi, Yuji Kozuka, Hiroto Yuasa, Yurina Nishimura, Makoto Ishitobi, Mikiya Ishihara, Toshiro Mizuno, Isao Tawara, Taizo Shiraishi, Tomoko Ogawa, Shinichi Kageyama, Yoshihiro Miyahara
{"title":"Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis.","authors":"Kaho Nakamura, Kanako Saito, Chihiro Higashi, Yuji Kozuka, Hiroto Yuasa, Yurina Nishimura, Makoto Ishitobi, Mikiya Ishihara, Toshiro Mizuno, Isao Tawara, Taizo Shiraishi, Tomoko Ogawa, Shinichi Kageyama, Yoshihiro Miyahara","doi":"10.1111/cas.16433","DOIUrl":"https://doi.org/10.1111/cas.16433","url":null,"abstract":"<p><p>Melanoma-associated antigen (MAGE)-A4, a cancer testis antigen, presents a promising target for chimeric antigen receptor T cell therapy in refractory solid tumors, including breast cancer (BC). However, the lack of highly specific Abs against MAGE-A4 is a major challenge for the development of MAGE-A4-targeted immunotherapies. This study aimed to validate the specificity of a novel MAGE-A4 Ab (E701U) and examine MAGE-A4 expression in clinical BC samples. MAGE-A1, -A2B, -A3, -A4, -A6, -A9, -A10, and -A12 genes were transfected into HEK293 cells. MAGE-A4 expression in each inserted cell block was evaluated using an E701U Ab. Subsequently, we evaluated MAGE-A4 expression in 403 primary BC tissue samples by immunohistochemistry using E701U and analyzed the clinical impact of MAGE-A4 in patients with early BC. The results showed that MAGE-A4 expression was limited to cells transduced with the MAGE-A4 gene. MAGE-A4 expression was observed in 5.7% of the BC samples. Positivity in triple-negative BC was significantly higher than in the other subtypes. The 5-year overall survival rate of patients with MAGE-A4(+) was significantly worse than those with MAGE-A4(-) BC. Moreover, the 5-year recurrence-free survival (RFS) rate of patients with MAGE-A4(+) BC was significantly lower than that of patients with MAGE-A4(-) BC. MAGE-A4 expression was an independent prognostic factor for RFS. In conclusion, the E701U Ab showed reliable specificity for MAGE-A4 expression among MAGE family genes. Patients with MAGE-A4(+) BC have an unfavorable prognosis and represent potential candidates for MAGE-A4-specific immunotherapy.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep learning detected histological differences between invasive and non-invasive areas of early esophageal cancer. 深度学习检测早期食管癌侵袭性和非侵袭性部位的组织学差异。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-18 DOI: 10.1111/cas.16426
Akiko Urabe, Masahiro Adachi, Naoya Sakamoto, Motohiro Kojima, Shumpei Ishikawa, Genichiro Ishii, Tomonori Yano, Shingo Sakashita
{"title":"Deep learning detected histological differences between invasive and non-invasive areas of early esophageal cancer.","authors":"Akiko Urabe, Masahiro Adachi, Naoya Sakamoto, Motohiro Kojima, Shumpei Ishikawa, Genichiro Ishii, Tomonori Yano, Shingo Sakashita","doi":"10.1111/cas.16426","DOIUrl":"https://doi.org/10.1111/cas.16426","url":null,"abstract":"<p><p>The depth of invasion plays a critical role in predicting the prognosis of early esophageal cancer, but the reasons behind invasion and the changes occurring in invasive areas are still not well understood. This study aimed to explore the morphological differences between invasive and non-invasive areas in early esophageal cancer specimens that have undergone endoscopic submucosal dissection (ESD), using artificial intelligence (AI) to shed light on the underlying mechanisms. In this study, data from 75 patients with esophageal squamous cell carcinoma (ESCC) were analyzed and endoscopic assessments were conducted to determine submucosal (SM) invasion. An AI model, specifically a Clustering-constrained Attention Multiple Instance Learning model (CLAM), was developed to predict the depth of cancer by training on surface histological images taken from both invasive and non-invasive regions. The AI model highlighted specific image portions, or patches, which were further examined to identify morphological differences between the two types of areas. The 256-pixel AI model demonstrated an average area under the receiver operating characteristic curve (AUC) value of 0.869 and an accuracy (ACC) of 0.788. The analysis of the AI-identified patches revealed that regions with invasion (SM) exhibited greater vascularity compared with non-invasive regions (epithelial). The invasive patches were characterized by a significant increase in the number and size of blood vessels, as well as a higher count of red blood cells (all with p-values <0.001). In conclusion, this study demonstrated that AI could identify critical differences in surface histopathology between non-invasive and invasive regions, particularly highlighting a higher number and larger size of blood vessels in invasive areas.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Two Faces of Angiopoietin-Like Protein 2 in Cancer. 肿瘤中血管生成素样蛋白2的两面。
IF 5.7 2区 医学
Cancer Science Pub Date : 2024-12-17 DOI: 10.1111/cas.16434
Haruki Horiguchi, Tsuyoshi Kadomatsu, Yuichi Oike
{"title":"The Two Faces of Angiopoietin-Like Protein 2 in Cancer.","authors":"Haruki Horiguchi, Tsuyoshi Kadomatsu, Yuichi Oike","doi":"10.1111/cas.16434","DOIUrl":"https://doi.org/10.1111/cas.16434","url":null,"abstract":"<p><p>The tumor microenvironment is composed of tumor cells and various stromal cell types, such as immune cells, fibroblasts, and vascular cells. Signaling interactions between tumor and stromal cells orchestrate the tumor microenvironment's contribution to tumor progression. Angiopoietin-like protein 2 (ANGPTL2) is a secreted glycoprotein homologous to angiopoietins. Previous studies indicate that tumor cell-derived ANGPTL2 serves as a tumor promoter. However, recent studies suggest that tumor stroma-derived ANGPTL2 shows tumor-suppressive activity by enhancing anti-tumor immune responses, supporting a dual function for ANGPTL2 in cancer pathology. Such complexity can complicate development of effective therapeutic strategies targeting ANGPTL2. In this Review, we focus on ANGPTL2 activity in the tumor microenvironment and its function in anti-cancer immunity.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信